We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

52 hedge funds and large institutions have $560M invested in Monte Rosa Therapeutics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 7 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

257% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 7

7.75% more ownership

Funds ownership: 78.13% → 85.88% (+7.7%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

2% less funds holding

Funds holding: 53 → 52 (-1)

25% less capital invested

Capital invested by funds: $742M → $560M (-$182M)

Holders
52
Holders Change
-1
Holders Change %
-1.89%
% of All Funds
0.82%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
10
Increased
25
Reduced
7
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$26.7M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$16.7M
3
BlackRock
BlackRock
New York
+$10.8M
4
State Street
State Street
Massachusetts
+$2.36M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.97M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$10.8M
2
APM
Avidity Partners Management
Texas
-$6.13M
3
OCA
Octagon Capital Advisors
New York
-$3.06M
4
VOYA Investment Management
VOYA Investment Management
Georgia
-$1.95M
5
E
Ergoteles
New York
-$1.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$108M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$98.1M +$259K +18,661 +0.3%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$75M +$16.7M +1,204,004 +29%
ACA
4
Avoro Capital Advisors
New York
$46.4M – – –
BlackRock
5
BlackRock
New York
$43.9M +$10.8M +774,628 +33%
Vanguard Group
6
Vanguard Group
Pennsylvania
$42.1M +$26.7M +1,922,156 +178%
CAM
7
Cormorant Asset Management
Massachusetts
$42.1M – – –
ACM
8
Aisling Capital Management
New York
$20.6M – – –
AI
9
Alphabet Inc
California
$20.5M – – –
RI
10
RTW Investments
New York
$17M – – –
CC
11
Casdin Capital
New York
$13.5M – – –
State Street
12
State Street
Massachusetts
$5.18M +$2.36M +169,992 +85%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$5.01M +$1.97M +141,674 +66%
Northern Trust
14
Northern Trust
Illinois
$3.08M +$1.55M +111,573 +103%
Bank of America
15
Bank of America
North Carolina
$2.07M +$1.14M +82,018 +125%
TD Asset Management
16
TD Asset Management
Ontario, Canada
$1.98M +$120K +8,678 +7%
Morgan Stanley
17
Morgan Stanley
New York
$1.89M -$17.5K -1,260 -0.9%
Charles Schwab
18
Charles Schwab
California
$1.76M +$560K +40,338 +47%
Allianz Asset Management
19
Allianz Asset Management
Germany
$1.3M +$1.28M +92,497 New
Manulife (Manufacturers Life Insurance)
20
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.26M +$1.28M +92,217 New
AllianceBernstein
21
AllianceBernstein
Tennessee
$1.14M -$123K -8,867 -10%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.04M +$588K +42,340 +132%
N
23
Nuveen
North Carolina
$802K +$536K +38,595 +153%
Goldman Sachs
24
Goldman Sachs
New York
$698K +$209K +15,071 +43%
WP
25
Woodline Partners
California
$674K +$1.04K +75 +0.2%
1
2 3

GLUE Hedge Fund Activity: Q1 2022 in Review

52 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q1 2022, worth a combined $560M — down 25% from $742M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of GLUE and 10 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 25 added.

The largest buyer was Vanguard Group, adding an estimated $26.7M. The largest seller was Jennison Associates, exiting entirely with an estimated $10.8M sold.

  • 52 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q1 2022, down from 53 in Q4 2021.
  • Funds reported $560M of Monte Rosa Therapeutics stock for Q1 2022, down 25% quarter-over-quarter.
  • 10 funds opened new Monte Rosa Therapeutics positions in Q1 2022 and 11 closed out, a net change of -1 holder.
  • The largest Monte Rosa Therapeutics buyer in Q1 2022 was Vanguard Group, an estimated $26.7M added.
  • The largest Monte Rosa Therapeutics seller in Q1 2022 was Jennison Associates, an estimated $10.8M sold.

Based on aggregated 13F filings for Q1 2022.